Floatz logo

Nab-Paclitaxel/Rituximab-Coated Nanoparticle Ar160

Recurrent Small Lymphocytic Lymphoma

Mayo ClinicunclassifiedPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

212 Active assets in the Recurrent Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Weill Medical College of Cornell University
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 4BBB
Apg-2575
Henan Cancer Hospital
Phase 3BBB
CHLORAMBUCIL
Ascentage Pharma Group Inc.
Phase 4BBB
Fludarabine
Roswell Park Cancer Institute
Phase 3BBB

View all 50 →

Same molecule, other indications

Nab-Paclitaxel/Rituximab-Coated Nanoparticle Ar160 is also rated in:

non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →